Congestive Heart Failure News and Research RSS Feed - Congestive Heart Failure News and Research

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.
Study: Certain prostate cancer medications linked to cardiac death risk

Study: Certain prostate cancer medications linked to cardiac death risk

A new study has found that certain prostate cancer medications are linked with an increased risk of dying from heart-related causes in men with congestive heart failure or prior heart attacks. Published in BJU International, the findings will help doctors and patients weigh the benefits and risks of the drugs. [More]
ASI treats first patient using Peregrine System Infusion Catheter

ASI treats first patient using Peregrine System Infusion Catheter

Ablative Solutions, Inc., a privately held company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has treated the first patient in the Peregrine Study. [More]
C3BS receives authorization to begin CHART-1 European Phase III trial for C-Cure in Switzerland

C3BS receives authorization to begin CHART-1 European Phase III trial for C-Cure in Switzerland

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure in Switzerland. [More]
Allscripts FollowMyHealth Achieve now available for patient engagement innovation

Allscripts FollowMyHealth Achieve now available for patient engagement innovation

Allscripts has announced the market launch and general availability of Allscripts FollowMyHealth Achieve, a consumer-friendly, patient engagement innovation intended to mobilize and empower patients as active partners in the management of their care. [More]
Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Colonoscopy is an important and widely used screening tool for colorectal cancer, but for many patients the bowel-preparation process is more uncomfortable than the procedure itself. To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015. [More]
Occlutech's Paravalvular Leak Closure Device European CE Mark approval

Occlutech's Paravalvular Leak Closure Device European CE Mark approval

Occlutech, a leading innovator of products to treat structural heart disease today announced that it has obtained a European CE Mark approval for its dedicated Paravalvular Leak Closure Device, (PLD). [More]
Caltech researcher explores link between variable heart rate, health and fitness

Caltech researcher explores link between variable heart rate, health and fitness

Although the heart beats out a very familiar "lub-dub" pattern that speeds up or slows down as our activity increases or decreases, the pattern itself isn't as regular as you might think. In fact, the amount of time between heartbeats can vary even at a "constant" heart rate-and that variability, doctors have found, is a good thing. [More]
Medicare experiment shows initial promise

Medicare experiment shows initial promise

Accountable care organizations, an Affordable Care Act model that rewards providers who produce better quality at lower cost, are showing promise in Wisconsin and Iowa. Meanwhile, a top Medicare adviser outlines other needed changes. [More]
RT with concurrent chemotherapy post surgery is effective for treating endometrial cancer

RT with concurrent chemotherapy post surgery is effective for treating endometrial cancer

Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for patients with high-risk endometrial cancer, according to a study published in the September 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). [More]
New iodine-based contrast material enhances CT images to safely use in most patients

New iodine-based contrast material enhances CT images to safely use in most patients

According to new research performed at the Mayo Clinic, iodine-based contrast material injected intravenously to enhance computed tomography (CT) images can be safely used in most patients. The study appears online in the journal Radiology. [More]
Viewpoints: Medicare no longer 'busting' the budget; a 'nightmare' trying to get coverage in D.C.

Viewpoints: Medicare no longer 'busting' the budget; a 'nightmare' trying to get coverage in D.C.

You're looking at the biggest story involving the federal budget and a crucial one for the future of the American economy. Every year for the last six years in a row, the Congressional Budget Office has reduced its estimate for how much the federal government will need to spend on Medicare in coming years. [More]
New wireless monitoring sensor helps doctors and patients manage heart failure problems

New wireless monitoring sensor helps doctors and patients manage heart failure problems

Unexpected trips to the hospital are inconvenient and worrisome for anyone, but for congestive heart failure sufferers, they can be all too frequent. [More]
Researchers identify predictors of early rehospitalization among patients with COPD

Researchers identify predictors of early rehospitalization among patients with COPD

Researchers at the University of Texas Medical Branch at Galveston have identified predictors of early rehospitalization among patients hospitalized for complications of chronic obstructive pulmonary disease. This study was recently published in the Annals of the American Thoracic Society. [More]
Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS). [More]
Household income plays key role in avoidable hospital visits across New Jersey

Household income plays key role in avoidable hospital visits across New Jersey

The household income of its residents is the most important factor in whether a community has high or low rates of avoidable hospital visits - conditions that could be better managed in a doctor's office or other health care settings if treated at an early stage, according to a report released today by the Rutgers Center for State Health Policy (CSHP). [More]
Cardioxyl reports positive results from CXL-1427 Phase I trial for treatment of ADHF

Cardioxyl reports positive results from CXL-1427 Phase I trial for treatment of ADHF

Cardioxyl Pharmaceuticals, Inc. announced today the positive results of a clinical trial demonstrating that CXL-1427, a novel potential treatment for acute decompensated heart failure (ADHF), was well tolerated in healthy volunteers. [More]
Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). [More]
PAH disease burden ‘significant’

PAH disease burden ‘significant’

Patients with newly diagnosed pulmonary arterial hypertension have a substantial burden of disease, with more than half hospitalised during the first 3 years post-diagnosis, research shows. [More]
Mercy Memorial Hospital System signs LOI to join Promedica

Mercy Memorial Hospital System signs LOI to join Promedica

Mercy Memorial Hospital System signed a letter of intent to join ProMedica, a not-for-profit, multi-hospital system based in Toledo, Ohio. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]